Figure 3
From: Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
The NSC23925 inhibited the introduction of cross-resistance to chemotherapeutic agents. The U-2OS/paclitaxel0.006–NSC23925 cells showed sensitivity to paclitaxel (A), docetaxel (B), doxorubicin (C), vincrisine (D), PM-00104 (E) and gemcitabine (F), whereas U-2OS/paclitaxel0.2 cells displayed resistance to these drugs. The cytotoxicity of cisplatin (G) and methotrexate (H) did not change in both U-2OS/paclitaxel0.006–NSC23925 and U-2OS/paclitaxel0.2 cells. No changes in cytotoxicity of chemotherapeutic agents were seen in U-2OS/NSC23925 cells. Data are presented as mean±s.d.
